BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
http://www.biogen.com

SectorHealthcare
SectorDrug Manufacturers—General
Empleados a tiempo completo7400

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Michel VounatsosCEO & Director5,02MN/A1962
Mr. Jeffrey D. CapelloExec. VP & CFO1,59MN/A1965
Ms. Susan H. AlexanderExec. VP, Chief Legal Officer & Sec.1,81MN/A1957
Ms. Robin C. KramerVP & Chief Accounting OfficerN/AN/A1966
Mr. Mark J. HernonSr. VP & Chief Information OfficerN/AN/A1964
Los importes son a partir de 31 de diciembre de 2018 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases, and related therapeutic adjacencies in the United States, Europe, Asia, and internationally. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA, as well as ophthalmology biosimilar products, such as SB11 referencing LUCENTIS and SB15 referencing EYLEA. The company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. It also develops Opicinumab, BIIB091, and BIIB061 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB100, and BIIB110 for neuromuscular disorders; BIIB094 and BIIB054 to treat movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and other diseases; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, BIIB093, and Natalizumab to treat acute neurology; and BIIB074 and BIIB095 for pain. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Biogen Inc., a día 3 de febrero de 2020, es 3. Las puntuaciones base son Auditoría: 1; Tablero: 6; Derechos de los accionistas: 2; Compensación: 7.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.
Al usar Yahoo aceptas que Yahoo y sus socios puedan utilizar cookies para personalización y otros fines